Sandbox Reserved 1705: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 18: | Line 18: | ||
== Applications == | == Applications == | ||
Anaplastic lymphoma kinase's involvement as a proto-oncogene in various types of cancers has made it a target for drug therapies for these types of cancers <ref name="Lewis">PMID:22734674</ref>. One therapeutic medication that has been increasingly used with high levels of success is Crizotinib. This medication was approved by the FDA in January of 2021 for the treatment of pediatric/young adult ALK-positive anaplastic large cell lymphoma. The treatment has an overall response rate of 90%. Crizotinib works by binding to the ATP binding site of the kinase domain <ref name="Sahu">PMID:24455567</ref>. Crizotinib binds preferentially to ATP in this region and therefore can effectively block the binding of ATP <ref name="Sahu" />. With the binding of ATP being blocked, the intercellular signaling cascade cannot begin which works to prevent the cancer from growing and spreading . | Anaplastic lymphoma kinase's involvement as a proto-oncogene in various types of cancers has made it a target for drug therapies for these types of cancers <ref name="Lewis">PMID:22734674</ref>. One therapeutic medication that has been increasingly used with high levels of success is Crizotinib. This medication was approved by the FDA in January of 2021 for the treatment of pediatric/young adult ALK-positive anaplastic large cell lymphoma. The treatment has an overall response rate of 90%. Crizotinib works by <scene name='90/904309/Kinase_crizotinib/1'>binding</scene> to the ATP binding site of the kinase domain <ref name="Sahu">PMID:24455567</ref>. Crizotinib binds preferentially to ATP in this region and therefore can effectively block the binding of ATP <ref name="Sahu" />. With the binding of ATP being blocked, the intercellular signaling cascade cannot begin which works to prevent the cancer from growing and spreading . | ||